Gammaked Injection
NDC Package 76125-900-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Gammaked (immune globulin (human)) injection is a medication used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This formulation utilizes a injection delivery system. Marketed by Kedrion Biopharma, Inc., this product is identified by NDC 76125-900 and is authorized under FDA application BLA125046.

Identification & Billing

NDC Package Code
76125-900-01
Package Description
1 VIAL, GLASS in 1 CARTON / 10 mL in 1 VIAL, GLASS (76125-900-02)
Product Code
11-Digit Billing Format
76125090001
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Gammaked
Non-Proprietary Name
Immune Globulin (human)
Substance Name
Human Immunoglobulin G
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
  • Intravenous - Administration within or into a vein or veins.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
Usage Information
This medication is used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This medication is made from human blood that has a high level of antibodies which help fight infections. This product is also used to increase the number of certain blood cells (platelets) in people with a certain blood disorder (idiopathic thrombocytopenic purpura-ITP). Platelets are needed to stop bleeding and to form normal blood clots. In addition, this medication is used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). This disorder causes weakness and numbness/tingling/pain in the arms and legs. This medication helps to improve these symptoms and prevents relapse.

Regulatory & Marketing

Labeler Name
Kedrion Biopharma, Inc.
Product Type
Plasma Derivative
FDA Application #
BLA125046
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-13-2010
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (76125-900). Click a package code to view its specific billing and regulatory data.

1 VIAL, GLASS in 1 CARTON / 100 mL in 1 VIAL, GLASS (76125-900-11)
1 VIAL, GLASS in 1 CARTON / 200 mL in 1 VIAL, GLASS (76125-900-21)
1 VIAL, GLASS in 1 CARTON / 25 mL in 1 VIAL, GLASS (76125-900-26)
1 VIAL, GLASS in 1 CARTON / 50 mL in 1 VIAL, GLASS (76125-900-51)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76125-900-01 identifies a specific commercial package of 1 vial, glass in 1 carton / 10 ml in 1 vial, glass (76125-900-02) of Gammaked, a plasma derivative labeled by Kedrion Biopharma, Inc.. This injection is formulated for intravenous; subcutaneous use and contains human immunoglobulin g as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kedrion Biopharma, Inc. on October 13, 2010. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This medication is made from human blood that has a high level of antibodies which help fight infections. This product is also used to increase the number of certain blood cells (platelets) in people with a certain blood disorder (idiopathic thrombocytopenic purpura-ITP). Platelets are needed to stop bleeding and to form normal blood clots. In addition, this medication is used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). This disorder causes weakness and numbness/tingling/pain in the arms and legs. This medication helps to improve these symptoms and prevents relapse.

How is this Kedrion Biopharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76125090001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
76125-900-01
11-Digit CMS (5-4-2)
76125-0900-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.